Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome

Qin,Xianyun; Liu,Jilan; Pan,Dongfeng; Ma,Wenyuan; Cheng,Panpan; Jin,Feng

doi:10.3892/or.2021.7985

Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome

Authors:
- Xianyun Qin
- Jilan Liu
- Dongfeng Pan
- Wenyuan Ma
- Panpan Cheng
- Feng Jin
View Affiliations

Affiliations: Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, P.R. China, Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA 22908, USA, Department of Neurosurgery, Affiliated Hospital of Jining Medical University and Shandong Provincial Key Laboratory of Stem Cells and Neuro‑Oncology, Jining, Shandong 272029, P.R. China, Department of Hematology Laboratory, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, P.R. China
Published online on: February 19, 2021 https://doi.org/10.3892/or.2021.7985
Article Number: 34
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is a type of common primary intracranial tumor, which is difficult to treat. It has been confirmed by research that corilagin (the primary active constituent of the matsumura leafflower herb) has significant antitumor effect. In particular, our previous research demonstrated that corilagin effectively promotes apoptosis of glioma U251 cells and has a synergistic effect when used with temozolomide. However, the mechanism by which corilagin causes apoptosis in U251 cells has yet to be investigated. Proteasomes are catalytic centers of the ubiquitin‑proteasome system, which is the major protein degradation pathway in eukaryotic cells; they are primarily responsible for the degradation of signal molecules, tumor suppressors, cyclins and apoptosis inhibitors and serve an important role in tumor cell proliferation and apoptosis. The present study investigated the pro‑apoptotic effect of corilagin on glioma U251 cells and confirmed that decreased proteasome activity and expression levels serve an important role in corilagin‑induced U251 cell apoptosis.

View Figures

View References

1	Gusyatiner O and Hegi ME: Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Yang Q, Zhou Y, Chen J, Huang N, Wang Z and Cheng Y: Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomedicine. 16:185–199. 2021. View Article : Google Scholar : PubMed/NCBI
5	Li X, Deng Y, Zheng Z, Huang W, Chen L, Tong Q and Ming Y: Corilagin, a promising medicinal herbal agent. Biomed Pharmacother. 99:43–50. 2018. View Article : Google Scholar : PubMed/NCBI
6	Wu C, Huang H, Choi HY, Ma Y, Zhou T, Peng Y, Pang K, Shu G and Yang X: Anti-esophageal cancer effect of corilagin extracted from phmllanthi fructus via the mitochondrial and endoplasmic reticulum stress pathways. J Ethnopharmacol. 269:1137002021. View Article : Google Scholar : PubMed/NCBI
7	Wan LF, Shen JJ, Wang YH, Zhao W, Fang NY, Yuan X and Xue BY: Extracts of Qizhu decoction inhibit hepatitis and hepatocellular carcinoma in vitro and in C57BL/6 mice by suppressing NF-κB signaling. Sci Rep. 9:14152019. View Article : Google Scholar : PubMed/NCBI
8	Qiu F, Liu L, Lin Y, Yang Z and Qiu F: Corilagin inhibits esophageal squamous cell carcinoma by inducing DNA damage and down-regulation of RNF8. Anticancer Agents Med Chem. 19:1021–1028. 2019. View Article : Google Scholar : PubMed/NCBI
9	Tong Y, Zhang G, Li Y, Xu J, Yuan J, Zhang B, Hu T and Song G: Corilagin inhibits breast cancer growth via reactive oxygen species-dependent apoptosis and autophagy. J Cell Mol Med. 22:3795–3807. 2018. View Article : Google Scholar
10	Iweala EEJ, Xu J, Zhang G, Tong Y, Yuan J, Li Y and Song G: Corilagin induces apoptosis, autophagy and ROS generation in gastric cancer cells in vitro. Int J Mol Med. 43:967–979. 2019.PubMed/NCBI
11	Yang WT, Li GH, Li ZY, Feng S, Liu XQ, Han GK, Zhang H, Qin XY, Zhang R, Nie QM and Jin F: Effect of corilagin on the proliferation and NF-κB in U251 glioblastoma cells and U251 glioblastoma stem-like Cells. Evid Based Complement Alternat Med. 2016:14183092016. View Article : Google Scholar : PubMed/NCBI
12	Milani R, Brognara E, Fabbri E, Finotti A, Borgatti M, Lampronti I, Marzaro G, Chilin A, Lee KK, Kok SH, et al: Corilagin induces high levels of apoptosis in the temozolomide-resistant T98G glioma cell line. Oncol Res. 26:1307–1315. 2018. View Article : Google Scholar : PubMed/NCBI
13	Lee J, Kim J, Kim EM, Kim U, Kang AR, Park JK and Um HD: p21^WAF1/CIP1 promotes p53 protein degradation by facilitating p53-Wip1 and p53-Mdm2 interaction. Biochem Biophys Res Commun. 543:23–28. 2021. View Article : Google Scholar : PubMed/NCBI
14	Sakata E, Eisele MR and Baumeister W: Molecular and cellular dynamics of the 26S proteasome. Biochim Biophys Acta Proteins Proteom. 1869:1405832021. View Article : Google Scholar : PubMed/NCBI
15	Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC and Martin A: Structure and function of the 26S proteasome. Annu Rev Biochem. 87:697–724. 2018. View Article : Google Scholar : PubMed/NCBI
16	Murata S, Takahama Y, Kasahara M and Tanaka K: The immunoproteasome and thymoproteasome: Functions, evolution and human disease. Nat Immunol. 19:923–931. 2018. View Article : Google Scholar : PubMed/NCBI
17	Rousseau A and Bertolotti A: Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 19:697–712. 2018. View Article : Google Scholar : PubMed/NCBI
18	Ettari R, Pallio G, Pizzino G, Irrera N, Zappalà M, Maiorana S, Di Chio C, Altavilla D, Squadrito F and Bitto A: Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells. J Enzyme Inhib Med Chem. 34:1307–1313. 2019. View Article : Google Scholar : PubMed/NCBI
19	Kuzina ES, Kudriaeva AA, Maltseva DV and Belogurov AA Jr: Peptidyl aldehyde specifically interacts with immunosubunit β1i proteasome: In vitro and in vivo effects. Bull Exp Biol Med. 161:69–71. 2016. View Article : Google Scholar : PubMed/NCBI
20	Sun C, Mo M, Wang Y, Yu W, Song C, Wang X, Chen S and Liu Y: Activation of the immunoproteasome protects SH-SY5Y cells from the toxicity of rotenone. Neurotoxicology. 73:112–119. 2019. View Article : Google Scholar : PubMed/NCBI
21	Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, Spencer B, Page L, Masliah E, Berggren WT, et al: Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature. 489:304–308. 2012. View Article : Google Scholar : PubMed/NCBI
22	Toste Rêgo A and da Fonseca PCA: Characterization of fully recombinant human 20S and 20S-PA200 proteasome complexes. Mol Cell. 76:138–147.e5. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hanssum A, Zhong Z, Rousseau A, Krzyzosiak A, Sigurdardottir A and Bertolotti A: An inducible chaperone adapts proteasome assembly to stress. Mol Cell. 55:566–577. 2014. View Article : Google Scholar : PubMed/NCBI
24	Collins GA and Goldberg AL: The logic of the 26S proteasome. Cell. 169:792–806. 2017. View Article : Google Scholar : PubMed/NCBI
25	Kuo CL and Goldberg AL: Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc Natl Acad Sci USA. 114:E3404–E3413. 2017. View Article : Google Scholar : PubMed/NCBI
26	Lokireddy S, Kukushkin NV and Goldberg AL: cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci USA. 112:E7176–E7185. 2015. View Article : Google Scholar : PubMed/NCBI
27	Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL and Duff KE: Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. 22:46–53. 2016. View Article : Google Scholar : PubMed/NCBI
28	Min L, Zeng X, Li B, Tao B, Shi J, Zhang W, Sun Q, Jing C and Wang X: Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma. Neuroreport. 30:1031–1038. 2019. View Article : Google Scholar : PubMed/NCBI
29	Qin XY, Zhang YL, Chi YF, Yan B, Zeng XJ, Li HH and Liu Y: Angiotensin II regulates Th1 T cell differentiation through angiotensin II type 1 receptor-PKA-mediated activation of proteasome. Cell Physiol Biochem. 45:1366–1376. 2018. View Article : Google Scholar : PubMed/NCBI
30	Ettari R, Previti S, Bitto A, Grasso S and Zappalà M: Immunoproteasome-selective inhibitors: A promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases. Curr Med Chem. 23:1217–1238. 2016. View Article : Google Scholar : PubMed/NCBI
31	Welk V, Coux O, Kleene V, Abeza C, Trümbach D, Eickelberg O and Meiners S: Inhibition of proteasome activity induces formation of alternative proteasome complexes. J Biol Chem. 291:13147–13159. 2016. View Article : Google Scholar : PubMed/NCBI
32	Mannhaupt G, Schnall R, Karpov V, Vetter I and Feldmann H: Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast. FEBS Lett. 450:27–34. 1999. View Article : Google Scholar : PubMed/NCBI
33	Zarfati M, Avivi I, Brenner B, Katz T and Aharon A: Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis. 22:185–196. 2019. View Article : Google Scholar : PubMed/NCBI
34	Park JE, Miller Z, Jun Y, Lee W and Kim KB: Next-generation proteasome inhibitors for cancer therapy. Transl Res. 198:1–16. 2018. View Article : Google Scholar : PubMed/NCBI
35	Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M and Groll M: Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell. 148:727–738. 2012. View Article : Google Scholar : PubMed/NCBI
36	Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 15:781–787. 2009. View Article : Google Scholar : PubMed/NCBI
37	Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C, Park SH, Sung KS, Choi SA, Hwang J, et al: Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 18:150–168. 2017. View Article : Google Scholar : PubMed/NCBI
38	Su L, Guo W, Lou L, Nie S, Zhang Q, Liu Y, Chang Y, Zhang X, Li Y and Shen H: EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Mol Carcinog. 59:520–532. 2020. View Article : Google Scholar : PubMed/NCBI
39	Yang XF, Zhao ZJ, Liu JJ, Yang XH, Gao Y, Zhao S, Shi S, Huang KQ and Zheng HC: SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study. Oncotarget. 8:3156–3169. 2017. View Article : Google Scholar : PubMed/NCBI
40	Tang JH, Yang L, Chen JX, Li QR, Zhu LR, Xu QF, Huang GH, Zhang ZX, Xiang Y, Du L, et al: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Cancer Commun (Lond). 39:812019. View Article : Google Scholar : PubMed/NCBI
41	Zhang M, Lu L, Ying M, Ruan H, Wang X, Wang H, Chai Z, Wang S, Zhan C, Pan J and Lu W: Enhanced Glioblastoma targeting ability of carfilzomib enabled by a DA7R-modified lipid nanodisk. Mol Pharm. 15:2437–2447. 2018. View Article : Google Scholar : PubMed/NCBI
42	Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, et al: Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: Safety and efficacy assessment. Int J Radiat Oncol Biol Phys. 100:1195–1203. 2018. View Article : Google Scholar : PubMed/NCBI
43	Liu H, Wan C, Ding Y, Han R, He Y, Xiao J and Hao J: PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing T_h17-cell differentiation and regulating cytokine production. FASEB J. 31:1756–1766. 2017. View Article : Google Scholar : PubMed/NCBI